TOBIRA THERAPEUTICS INC

Inactive Instrument

Tobira Therapeutics Inc Stock Nasdaq

Equities

US75874Q1076

Biotechnology & Medical Research

Chart Tobira Therapeutics Inc

Duration

Period

Style

Press releases Tobira Therapeutics Inc

Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	16-10-20	BU
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	16-10-03	BU
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	16-09-21	BU
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	16-09-20	PU
Tobira Therapeutics : Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin	16-09-12	BU

More press releases

News in other languages on Tobira Therapeutics Inc

TOBIRA fait gagner plus de 40 000 euros à un investisseur !

16-10-26

Managers and Directors - Tobira Therapeutics Inc

Managers	Title	Age	Since
Robert Michael CEO	Chief Executive Officer	53	-
Scott Reents DFI	Director of Finance/CFO	57	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B

Bio Therapeutic Drugs

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer